Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
286
Recruiting, industry sponsors, Hematology and blood cancers, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting286
- Completed1,361
286 trials
Showing 1 to 25, recently updated first.
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04811560 · 494 participants (planned) · Start May 19, 2021 · Primary completion Dec 29, 2028
Drug: Bleximenib · For: Acute Leukemia; Primary Myelofibrosis; Essential Thrombocythemia
Sites: Duarte, California; Orange, California; San Francisco, California · 102 sites in all
Orca Biosystems, Inc.Industry
NCT07216443 · 130 participants (planned) · Start Dec 9, 2025 · Primary completion Nov 2028
Drug: Orca-T · For: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Mixed Phenotype Acute Leukemia
Sites: Duarte, California; Los Angeles, California; Denver, Colorado · 9 sites in all
Tethra Biosciences Inc.Industry
NCT05358379 · 330 participants (planned) · Start Apr 14, 2022 · Primary completion Nov 2028
Drug: THT140 · For: Solid Tumor, Adult Lymphoma
Sites: New York, New York; Houston, Texas; Seattle, Washington · 5 sites in all
- A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT05714839 · 123 participants (planned) · Start Jun 14, 2023 · Primary completion Aug 3, 2028
Drug: Belantamab; Belantamab mafodotin and 2 more · For: Multiple Myeloma
Sites: Bullhead City, Arizona; Los Angeles, California; Pembroke Pines, Florida · 59 sites in all
- A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)Recruiting
ScinnoHub Pharmaceutical Co., Ltd.Industry
NCT07579949 · 30 participants (planned) · Start Jun 16, 2026 · Primary completion Sep 30, 2027
Drug: SNH-119014 dose 1; SNH-119014 dose 2 and 1 more · For: Thalassemia
Sites: Foshan, China; Guangzhou, China; Maoming, China · 8 sites in all
AbbVieAbbVie (ABBV)
NCT07581002 · 660 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2032
Drug: Pivekimab Sunirine; Venetoclax and 2 more · For: Acute Myeloid Leukemia
Sites: Duarte, California; Tampa, Florida; Atlanta, Georgia · 40 sites in all
- A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)Pivotal-lookingRecruiting
Swedish Orphan BiovitrumIndustry
NCT06782373 · 156 participants (planned) · Start May 28, 2025 · Primary completion Oct 30, 2028
Drug: Pacritinib; Placebo · For: VEXAS; VEXAS Syndrome
Sites: Scottsdale, Arizona; Boston, Massachusetts; Rochester, Minnesota · 39 sites in all
- A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerPivotal-lookingRecruiting
Recursion Pharmaceuticals Inc.Industry
NCT06678659 · 310 participants (planned) · Start Nov 21, 2024 · Primary completion Jul 2029
Drug: REC-1245 · For: Unresectable; Locally Advanced; Metastatic Cancers and 1 more
Sites: Duarte, California; Palo Alto, California; Santa Monica, California · 8 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06292780 · 220 participants (planned) · Start Aug 7, 2024 · Primary completion Aug 20, 2028
Drug: Linvoseltamab · For: Relapsed/Refractory Systemic Light Chain Amyloidosis
Sites: Duarte, California; Denver, Colorado; Boston, Massachusetts · 24 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06379789 · 130 participants (planned) · Start Sep 11, 2024 · Primary completion Aug 14, 2034
Drug: REGV131; LNP1265 · For: Hemophilia B
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 54 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04728893 · 490 participants (planned) · Start Apr 5, 2021 · Primary completion Jan 4, 2029
Drug: Nemtabrutinib · For: Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma and 1 more
Sites: Springdale, Arkansas; La Jolla, California; Torrance, California · 121 sites in all
- A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)Pivotal-lookingRecruiting
Debiopharm International SAIndustry
NCT06969430 · 154 participants (planned) · Start May 30, 2025 · Primary completion Nov 2031
Drug: Debio 1562M · For: Acute Myeloid Leukemia
Sites: Duarte, California; Tampa, Florida; Chicago, Illinois · 7 sites in all
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07421167 · 164 participants (planned) · Start Aug 4, 2026 · Primary completion Jan 18, 2029
Drug: ianalumab; thrombopoietin receptor agonist (TPO-RA) · For: Primary Immune Thrombocytopenia (ITP); Primary Evans Syndrome (ES)
Sites: Chandler, Arizona; Fayetteville, Arkansas; Torrance, California · 24 sites in all
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT04643002 · 258 participants (planned) · Start Jan 25, 2021 · Primary completion Sep 13, 2027
Drug: Isatuximab; Dexamethasone and 6 more · For: Plasma Cell Myeloma Refractory
Sites: Birmingham, Alabama; Atlanta, Georgia; Chicago, Illinois · 28 sites in all
Debiopharm International SAIndustry
NCT05765812 · 116 participants (planned) · Start May 15, 2023 · Primary completion Sep 2028
Drug: Zedoresertib; Temozolomide · For: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype; Astrocytoma, Grade III
Sites: Chicago, Illinois; New York, New York; Dallas, Texas · 16 sites in all
Nurix Therapeutics, Inc.Industry
NCT07221500 · 100 participants (planned) · Start Oct 15, 2025 · Primary completion Jan 2028
Drug: NX-5948 · For: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Sites: Phoenix, Arizona; Duarte, California; Irvine, California · 47 sites in all
Nurix Therapeutics, Inc.Industry
NCT07520006 · 150 participants (planned) · Start Sep 30, 2026 · Primary completion May 2033
Drug: NX-5948; venetoclax and 2 more · For: B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Irvine, California; Aurora, Colorado; Coral Gables, Florida · 10 sites in all
- A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07194850 · 24 participants (planned) · Start Oct 20, 2025 · Primary completion Oct 2028
Drug: Efgartigimod IV · For: Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia; ITP and 4 more
Sites: Bordeaux, France; La Tronche, France; Vandœuvre-lès-Nancy, France · 28 sites in all
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06806033 · 130 participants (planned) · Start Mar 5, 2025 · Primary completion Jul 31, 2029
Drug: Obinutuzumab; Glofitamab and 2 more · For: Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Sites: Anchorage, Alaska; Clovis, California; Fullerton, California · 53 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06890884 · 594 participants (planned) · Start Apr 11, 2025 · Primary completion Dec 13, 2027
Drug: Zilovertamab vedotin; Rituximab and 7 more · For: Lymphoma, Large B-Cell, Diffuse
Sites: Mobile, Alabama; Chandler, Arizona; Glendale, Arizona · 148 sites in all
Faron Pharmaceuticals LtdIndustry
NCT07672769 · 90 participants (planned) · Start Nov 2026 · Primary completion Nov 2027
Drug: bexmarilimab (1mg/kg); azacitidine and 2 more · For: Higher Risk Myelodysplastic Syndromes
Sites: Duarte, California; Aurora, Colorado; New Haven, Connecticut · 35 sites in all
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07634471 · 960 participants (planned) · Start Jun 22, 2026 · Primary completion Jul 23, 2032
Drug: MK-1045; Rituximab and 7 more · For: Follicular Lymphoma
Sites: Duarte, California; Lexington, Kentucky; Hackensack, New Jersey · 40 sites in all
Incyte Biosciences International SàrlIncyte (INCY)
NCT03934372 · 70 participants (planned) · Start Jan 29, 2020 · Primary completion Feb 1, 2028
Drug: Ponatinib · For: Acute Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blast Phase Chronic Myeloid Leukemia and 6 more
Sites: Ghent, Belgium; Paris, France; Poitiers, France · 23 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07709000 · 60 participants (planned) · Start Oct 14, 2026 · Primary completion Nov 16, 2033
Drug: MK-1045; Acetaminophen (or similar antipyretic) and 5 more · For: Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Hematologic Malignancies
Sites: Medellín, Colombia; Bogotá, Colombia; Haifa, Israel · 10 sites in all
- A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07519772 · 280 participants (planned) · Start May 3, 2026 · Primary completion Jul 1, 2030
Drug: MK-1045 · For: Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
Sites: Los Angeles, California; Denver, Colorado; Cleveland, Ohio · 56 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.